Research Progress on CALR Mutation in the Myeloproliterative Neoplasm -Review.
10.7534/j.issn.1009-2137.2016.04.054
- Author:
Jun YUAN
1
;
Hong-Ling HAO
2
;
Yan LI
1
;
Rui-Cang WANG
1
;
Xiao-Xia ZHANG
1
Author Information
1. Department of Hematology, Hebei People's Hospital, Shijiazhang 050000, Hebei Province, China.
2. Department of Hematology, Hebei People's Hospital, Shijiazhang 050000, Hebei Province, China.E-mail: h0707@163.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow;
Bone Marrow Cells;
Calreticulin;
Humans;
Mutation;
Myeloproliferative Disorders;
Prognosis
- From:
Journal of Experimental Hematology
2016;24(4):1252-1255
- CountryChina
- Language:Chinese
-
Abstract:
There is no gold diagnostic standard for BCR-ABL fusion gene negative chronic myeloproliterative neoplasm(cMPN). The following detection methods such as comprehensive bone marrow cell morphology, bone marrow pathology, genetic mutation, flow cytometry and immunohistochemical are needed to diagnose the BCR-ABL fusion gene positive cMPN. The JAK2 mutation can be used as a specific diagnostic criteria for polycythemia vera (PV), but there is no specific and sensitive indication for the JAK2 mutation-negative MPN. CALR mutation would be an indication in a certain extent. In this review, the CALR mutation detection, detection mean and its correlation with disease diagnosis and prognosis etc were summarized.
